• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

NIHR Oxford Health Biomedical Research Centre

Improving brain health: the future in mind

MENUMENU
  • About
    • About
    • Our People
    • Timeline of our key achievements since 2017
    • Core facilities
    • Management and partners
    • Work with us
    • Contact
  • Departments
    • NIHR Oxford Cognitive Health Clinical Research Facility
    • Brain Health Centre
    • Oxford Precision Psychiatry Lab (OxPPL)
    • Oxford Dementia and Ageing Research (OxDARE)
    • Treatment Resistant Depression Clinic
    • Experimental Medicine and Industry Partnership (EMIP)
  • Research Themes
    • Overview of Research Themes
    • Adult Mental Health
    • Older Adults and Dementia
    • Precision Psychological Therapies
    • Clinical Research Infrastructure and Experimental Medicine
    • Informatics and Digital Health
    • Neuroimaging and Cognitive Neuroscience
    • Patient and Public Involvement
    • Training theme
    • Theme Leads
  • COVID-19 Research
    • Overview
    • News
    • COVID-19 & clinical management of mental health issues
  • News & Events
    • News
    • Blog
    • Training & Events
    • Psychiatry department seminars
  • Training Hub
  • Patients & Public
    • About Patient and Public Involvement
    • Shape our research
    • Take part in our research
    • Resources for researchers
    • Resources for the public
    • Patient and Public Involvement Strategy
    • Young people’s involvement
You are here: Home / Departments / Case Studies / CASE STUDY 5 – A breakthrough approach to quickly and accurately matching individual patients to the right antidepressants

CASE STUDY 5 – A breakthrough approach to quickly and accurately matching individual patients to the right antidepressants


Why is this research important?

Depression is a common mood disorder but can have serious consequences for patients’ quality of life. The symptoms can be severe, profoundly affecting how people feel, think, and cope with daily activities, such as sleeping, eating, or working. Depression is caused by a range of genetic, biological, environmental and psychological factors – singly or in combination. In the UK alone, 3 million people live with depression today and 1 in 10 of us will be affected by it during our lifetimes. Every year, nearly 10 million working days are lost to depression.

And yet, there are many proven treatments for depression out there and we know that they can be highly effective. The problem is that there is currently no way of quickly and accurately finding the right medication for individual patients. Clinicians assess how individual patients respond to different medications and change their medication accordingly. But with 50-60% of patients not improving on the first antidepressant they try – and each new treatment taking around 6 weeks to show whether or not it’s effective – this can be a lengthy and distressing, delay and an inefficient use of time and resources. What’s needed is a quicker, more accurate way of knowing which medication will work best for any specific patient.


What are we doing?

Pioneering work by Professor Catherine Harmer and her team has given us a new understanding of the ways antidepressants work. They have developed a unique test to measure how patients respond to negative, positive and ambiguous images of human facial expression within the first week of antidepressant medication.

People with depression demonstrate a negative bias in their assessments of these images, interpreting them more negatively than people who are not depressed. Further, antidepressants act to make people more positive in their interpretations of the faces. We’ve seen that these changes in how people assess the faces occur quickly after starting antidepressants and are a highly promising indication of whether the patient will go on to respond to the antidepressant in the longer term.

This research forms the basis of a very large RCT (Randomised Controlled Trial) called the PReDicT trial which is assessing the effectiveness of the test. This study has been running for 3 years to date by our industrial collaborators, P1vital Ltd. It has assessed 900 patients across Europe, each of whom was part of the study for 12 months.

“This project is immensely exciting. It is testing the possibility that we can use cutting-edge advances in cognitive neuroscience to improve the treatment of patients with depression.”

Michael Browning: Chief Investigator – RCT

What do we hope to achieve?

Traditionally, to measure the effectiveness of antidepressants, clinicians would have to wait for up to 6 weeks before patients felt able confidently to say whether or not they felt more or less depressed. If our study reveals that the test helps match specific patients to the best medication for them faster, then we’ll have taken a major step forwards in shortening recovery times, improving outcomes and reducing the burden depression imposes on so many people.

Primary Sidebar

  • Case Studies Summary
  • CASE STUDY 1 – The Brain Health Centre – bringing research and clinical services together for better patient outcomes
  • CASE STUDY 2 – Accelerating the development of more effective antidepressants to improve patient outcomes
  • CASE STUDY 3 – A new approach to measuring memory in people at high risk of Alzheimers
  • CASE STUDY 4 – How, why, and when cardiovascular risk factors impact brain health
  • CASE STUDY 5 – A breakthrough approach to quickly and accurately matching individual patients to the right antidepressants
  • CASE STUDY 6 – A multidisciplinary trial reveals the potential of breakthrough research to better diagnose and treat psychosis patients

Footer

Follow us

  • Twitter
  • YouTube

Improving brain health: the future in mind

The National Institute for Health Research (NIHR) Biomedical Research Centre (BRC) is a partnership between Oxford Health NHS Foundation Trust and the University of Oxford. We are part of the Oxford Academic Health Science Centre.

Oxford Academic Health Science Centre
  • Sitemap
  • Accessibility
  • Disclaimer
  • Cookies
  • Contact

© 2022 NIHR Oxford Health Biomedical Research Centre · Log in

Cookies

This site uses cookies: See our privacy policy